Ipsen announced Monday it is voluntarily withdrawing its Tazverik cancer drug from all markets after emerging data showed risks may outweigh benefits due to secondary hematologic malignancies.
- “While this is an extremely disappointing outcome, the safety of patients remains our priority”, said Christelle Huguet, PhD & EVP Head of R&D at Ipsen. “Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation”
- Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma and epithelioid sarcoma
- Ipsen’s decision to withdraw is based on emerging data from the ongoing ...
- Ipsen’s decision to withdraw is based on emerging data from the ongoing ...